Pharmacyclics LLC is an American biopharmaceutical company based in Sunnyvale, California.

[3][4] In 2017, Xynomic Pharmaceuticals acquired all global rights to Abexinostat, Pharmacyclics' primary commercial product.

[5] In March 2015, Chicago-based biopharmaceutical firm AbbVie announced it would acquire Pharmacyclics, as well as its lead anti-cancer compound ibrutinib (Imbruvica) for $21 billion.

[7] Duggan will receive over $3.55 billion from the sale of Pharmacyclics to AbbVie in "one of the biggest paydays ever from the buyout of a publicly held company.

"[8][9][10][11][12] As CEO and chairman of Pharmacyclics since 2008, Robert Duggan has opted not to receive compensation from the company.